MedTrace Logo

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

NCT01059929 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2018-07-03

Study results available
· View outcomes & findings →

Summary

This is a randomized controlled trial to compare propofol to dexmedetomidine for prolonged sedation (\> 24 hours) in critically ill patients who require mechanical ventilation.

Conditions

  • Mechanical Ventilation
  • Critical Illness

Interventions

DRUG

Dexmedetomidine

continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS

DRUG

Propofol

continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS

DRUG

Fentanyl

25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale

DRUG

Midazolam

0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS\>+2)

BEHAVIORAL

Physical and Occupational Therapy

Daily therapy sessions targeting range of motion, strength, and mobility

Sponsors & Collaborators

  • Hospira, now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • John P Kress, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01059929 on ClinicalTrials.gov